Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature

Objective: Combination therapy with programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors might be viewed as a promising therapeutic strategy for resistant lung cancer, and it is becoming common that a second PD-1/PD-L1 inhibitor might be used following progres...

Full description

Bibliographic Details
Main Authors: Xiuju Liang, Yaping Guan, Bicheng Zhang, Jing Liang, Baocheng Wang, Yan Li, Jun Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Oncology
Subjects:
immune-related adverse event
programmed cell death 1 inhibitor
programmed cell death ligand 1
pneumonitis
immune checkpoint inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01437/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01437/full

Similar Items